Brief: Regeneron To Acquire Decibel Therapeutics, Strengthening Gene Therapy And Hearing Loss Programs
09/08/2023 14:16
Aug 9 (Reuters) - Decibel Therapeutics Inc DBTX.O :
* REGENERON TO ACQUIRE DECIBEL THERAPEUTICS, STRENGTHENING
GENE
THERAPY AND HEARING LOSS PROGRAMS
* REGENERON PHARMACEUTICALS INC - PROPOSED DEAL FOR A PRICE
OF
$4.00 PER SHARE
* REGENERON PHARMACEUTICALS INC - PROPOSED ACQUISITION
VALUES
DECIBEL AT A TOTAL EQUITY VALUE OF APPROXIMATELY $109 MILLION
* REGENERON - DEAL INCLUDES ADDITIONAL NON-TRADEABLE CVR TO
GET UP
TO $3.50/SHARE IN CASH UPON ACHIEVEMENT OF SOME MILESTONES
Source text for Eikon: ID:nGNX4m06zD
Further company coverage: DBTX.O
Recent news on Decibel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Domo, BlackBerry, Rite Aid
U.S. STOCKS ON THE MOVE-Decibel Therapeutics, Affirm Holdings, Medtronic
Decibel rises on FDA's 'fast-track' tag for hearing-loss therapy
Brief: Decibel Therapeutics Says US Food And Drug Administration Had Granted Fast Track Designation For DB-OTO
Decibel Therapeutics Inc reports results for the quarter ended in June - Earnings Summary